Genmab-partner Seagen strikes deal on Chinese rights for Tivdak

Exclusive commercial rights in China for the cervical cancer treatment jointly developed by Seagen and Genmab have been obtained by Zai Lab.

Photo: Lars Møller / Genmab / PR

US-based Seagen has entered a regional strategic collaboration and licensing deal concerning cervical cancer treatment Tivdak with Zai Lab, a pharmaceutical company based in China, a company press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs